Newsletter | June 14, 2026
RESPONDING TO RAPID CHANGE
Relentless technological change and scientific discovery means that companies (and people) can’t be experts in everything. This week’s selections from Life Science Leader provide distinct expert insights on the biotech business model, counterfeit product risk, and a grab bag of industry issues top of mind for the Life Science Connect (LSC) group of (expert) editors. On business model, scientific advances and emergent technologies are making platform-based therapeutic development more scalable, and modular, than ever before.
Drug diversion isn’t a topic we cover very often, but when it happens to biotech products, the impact can be catastrophic, writes former federal prosecutor Joseph Tartakovsky. Safeguarding product integrity has never been more urgent.
On the Business of Biotech, the LSC editors came together once again to discuss the biggest industry issues in their respective coverage areas, and what to expect in the second half of 2026.
Check out a curated selection from our partners, below, and thanks as always for reading.
Ben Comer Chief Editor, Life Science Leader
Paradigm Health reveals how eSource readiness now shapes site selection, accelerating connected trials — explore what scalable adoption really requires.
Worldwide Flex shows how AI and open-source tools are redefining biostatistics, demanding new expertise across increasingly modular development environments.
ISPOR examines how drug pricing policies may unintentionally reshape innovation pipelines, challenging how biotech hubs prioritize and fund R&D.
AutoCruitment highlights how advanced, patient-first recruitment strategies are transforming enrollment, helping distributed trial networks respond faster to demand.
Mural Health revisits industry predictions to show how rapidly trial models evolve, offering lessons for adapting strategy in uncertain environments.
CSS argues community-rooted recruitment is essential to access, emphasizing trust-building within decentralized, networked clinical trial ecosystems.
20/20 Onsite demonstrates how small inconsistencies in endpoint execution can derail outcomes, reinforcing the need for standardized expertise across sites.
Relentless technological change and scientific discovery means that companies (and people) can’t be experts in everything. This week’s selections from Life Science Leader provide distinct expert insights on the biotech business model, counterfeit product risk, and a grab bag of industry issues top of mind for the Life Science Connect (LSC) group of (expert) editors. On business model, 
